This report provides analysis of the global market for liquid biopsy products for the diagnosis and management of cancer. Regions covered by this report include North America, Europe, Asia Pacific, and the rest of the world (which combines estimated sales data for all other countries).
Published: 09 August 2018
Number of pages:88
This report provides analysis of the global market for liquid biopsy products for the diagnosis and management of cancer. Regions covered by this report include North America, Europe, Asia Pacific, and the rest of the world (which combines estimated sales data for all other countries). The global market for liquid biopsy products is anticipated to see rapid growth throughout the forecast period covered by this analysis (2017-22). Increased testing volume and growth in product sales is being driven by a number of factors, including an aging global population and the increasing burden of cancer worldwide, as well as innovation in sequencing technology. This analysis includes a discussion of liquid biopsy products, estimated market forecasts, competitive insights, and opportunities and challenges in the global liquid biopsy products market.
Primary research querying oncologists and key opinion leaders in the US was conducted in order to formulate forecasts and analysis.
Global product sales are projected to increase at a compound annual growth rate (CAGR) of 27.2%, increasing from approximately $611.4m in 2017 to an estimated $2,036.2m in 2022.
An overview of liquid biopsy products used in the diagnosis and management of cancer patients for different clinical applications such as early disease detection, therapy selection (companion diagnostics), and response to therapy.
Global and region-specific market forecasts.
Forecasts by product segments.
Competitive analyses of industry leaders and disruptive new competitors.
Discussion of key drivers and limiters impacting the major product segments.
Primary research with oncologists and key opinion leaders from the US focused on how they are utilizing these assays and their preferred/most frequently utilized manufacturers.
A review of emerging technologies which could impact sales of existing assays.
Total sales for liquid biopsy products are increasing rapidly as a result of a number of factors, including: the increasing prevalence of cancer, advances in sequencing and liquid biopsy technologies, and demand for alternatives to the current “gold standard,” tissue biopsy.
In 2017, circulating tumor cell-based assays accounted for the largest share of total liquid biopsy product sales. However, during the forecast period (2017-22) circulating tumor DNA-based assays will become the largest biomarker segment in the liquid biopsy market due to the perceived benefits of ctDNAcapture and analysis over other biomarkers.
The global market for liquid biopsy products is anticipated to increase at a CAGR of 27.2% during the forecast period, reaching approximately $2,036.25m in total product sales by 2022.
In 2017, North America was the largest region for liquid biopsy product sales, with an estimated market share of 46%. Europe was the second largest region in 2017; however, Meddevicetracker estimates that the AsiaPacific region will surpass Europe in market share during this report’s forecast period due to a rapid increase in test volume and large cancer burdens in these countries.
Extracellular vesicle/exosome-based assays will see the strongest growth out of all biomarker types.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.